Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

		Lugarri	iiiig. Ai									
AMICUS T Form 4 June 07, 20	THERAPEUTICS	INC										
OMB APPRO												
UNITED STATES SECONTIES AND EXCHANCE COMMISSION										3235-0287		
Check this box Washington, D.C. 20549									Number:	January 31,		
if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP O								RSHIP OF	Expires:	2005		
subject Section	10		RITIES			Estimated average burden hours per						
Form 4		5200	SECONTIES					s per 0.5				
Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,												
obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section												
<i>See</i> Instruction 30(h) of the Investment Company Act of 1940												
1(b).												
(Print or Type	e Responses)											
1. Name and Address of Reporting Person * 2. Issue PERRY MARK W Symbol					nd Ticker or Tr	ading		5. Relationship of Reporting Person(s) to Issuer				
		RAPEUTICS	S INC	2								
		[FOLD)]				(Check all applicable)					
(Last)	(First) (t) (Middle) 3. Date o			Fransaction		_	DirectorX10% Owner				
(Month/ 1119 ST. PAUL STREET 06/05/				n/Day/Year) /2007				Officer (give titleOther (specify below) below)				
(Street) 4. If Am				nendment, Date Original				6. Individual or Joint/Group Filing(Check				
Filed(Mc				onth/Day/Year)				Applicable Line)				
ΒΔΙ ΤΙΜ	DRE, MD 21202					_X_ Form filed by One Reporting Person Form filed by More than One Reporting						
	JKL, MID 21202						Pe	erson				
(City)	(State)	(Zip)	Tal	ble I - Non-	Derivative Se	curiti	es Acqui	ed, Disposed of,	or Beneficiall	y Owned		
1.Title of	2. Transaction Date			3.	4. Securities		red (A)	5. Amount of	6.	7. Nature of		
Security (Instr. 3)	(Month/Day/Year)	Execution Date, if any						Securities	Ownership Form:	Indirect Beneficial		
(111501.5)		(Month/Da	ay/Year)		(insu: <i>3</i> , 4 an	u 5)		Beneficially Owned	Form: Direct (D)) Ownership		
								Following	or Indirect			
						(A)		Reported Transaction(s)	(I) (Instr. 4)			
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)				
Common	0610510007							2 (50 400	т	See Note		
Stock	06/05/2007			С	3,650,488	А	<u>(1)</u>	3,650,488	Ι	2 (2)		
Common							\$		_	See Note		
Stock	06/05/2007			$X^{(4)}$	15,077	А	6.375	3,665,565	Ι	2 (2)		
Common										See Note		
Stock	06/05/2007			S <u>(4)</u>	6,408	D	\$ 15	3,659,157	Ι	$2 \frac{(2)}{2}$		
Common										See Note		
Stock	06/05/2007			С	821,736	А	<u>(1)</u>	821,736	Ι	$3 \frac{(3)}{3}$		
S to on										_		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Securit Acquire Dispose	ive	6. Date Exercisab Date (Month/Day/Year	7. Title and Underlying (Instr. 3 and	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Series B Convertible Preferred Stock	<u>(1)</u>	06/05/2007		С	1	990,796	<u>(1)</u>	<u>(1)</u>	Common Stock
Series C Convertible Preferred Stock	<u>(1)</u>	06/05/2007		C	1	,016,220	<u>(1)</u>	<u>(1)</u>	Common Stock
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007		C	1	,643,472	<u>(1)</u>	<u>(1)</u>	Common Stock
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007		С	:	821,736	<u>(1)</u>	<u>(1)</u>	Common Stock
Series B Convertible Preferred Stock Warrant (Right to Buy)	\$ 6.375	06/05/2007		Х		15,077	05/04/2004 <u>(5)</u>	05/04/2014 <u>(5)</u>	Commor Stock

Reporting Owners

 Reporting Owner Name / Address
 Relationships

 Director
 10% Owner
 Officer
 Other

 PERRY MARK W
 X
 X
 1119 ST. PAUL STREET
 V
 V

BALTIMORE, MD 21202

Signatures

/s/ Shawn Conway, attorney-in-fact <u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock
(1) automatically converted into the Issuer's common stock on a one for one basis upon the closing of the Issuer's initial public offering on June 5, 2007.

The Reporting Person is an individual manager of NEA 11 GP, LLC, the sole general partners of NEA Partners 11, Limited Partnership, the sole general partner of New Enterprise Associates 11, Limited Partnership ("NEA 11"), which is the beneficial owner of the securities.

(2) The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 11 shares in which the Reporting Person has no actual pecuniary interest therein.

(3) The Reporting Person is a general partner of NEA Partners 9, Limited Partnership, the sole general partner of New Enterprise Associates
 (3) 9, Limited Partnership ("NEA 9"), which is the beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 9 shares in which the Reporting Person has no actual pecuniary interest therein.

- (4) Net exercise of warrant held by New Enterprise Associates 11, Limited Partnership for an aggregate acquisition of 8,669 shares of Common Stock.
- (5) The warrant was net exercised upon the closing of the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.